Correction to: Cell Discovery (2017) 3, 17029

https://doi.org/10.1038/celldisc.2017.29 published online 12 September 2017

In the original publication of this article1, Figure 3b, upper panel, the image of colony formation/untreated (UT) HeyA8-MDR cells group was inadvertently duplicated in the next position for the group of “miR-18a-3p treated HeyA8-MDR” during preparation. This Figure panel was an unintended error and happened when assembling the original data, but did not influence the figure legend, or the interpretation of results. We provided a corrected version of Fig. 3b colony formation for HeyA8-MDR cells with a new representative image. The correct Fig. 3b upper panel is displayed below.

In Fig. 4c, the TUNEL staining panel for the “Anti-miR-Negative control + DXT” SKOV3ip1 group was inadvertently duplicated in the next position for the SKOV3-TR group of “Anti-miR-Negative control + DXT”. We have attached a corrected version of Fig. 4c TUNEL staining panels with a new representative image for the SKOV3ip1 group of “Anti-miR-Negative control + DXT”.

The correct figure legends are below.

Fig. 3 miR-25-3p and/or miR-15a-5p promote proliferation, colony formation, migration, and invasion of ovarian cancer cells. (a) Cell viability, (b) colony formation, and (c) invasion of HeyA8-MDR and SKOV3-TR cells treated with anti-miR-25-3p, anti-miR-15a-5p, a combination of the two anti-miRs or negative control anti-miR. UT, untreated. d Migration of HeyA8-MDR cells treated with anti-miR-25-3p, anti-miR-15a-5p, a combination of the two anti-miRs or negative control anti-miR. Yellow lines delimited the scratch starting point. Results for cell viability are presented as normalized means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.

Fig. 4 Anti-miR-25-3p, anti-miR-15a-5p, and docetaxel (DXT) have antitumor effects in ovarian cancer mouse models. SKOV3IP1 or resistant SKOV3-TR ovarian tumor-bearing mice treated with anti-miR-25-3p and/or anti-miR-15a-5p (200 μg kg−1 body weight/intravenous) plus DXT (75 μg intraperitoneally) for 5 weeks exhibited lower tumor weights (a), fewer tumor nodules (b), more TUNEL (terminal Deoxynucleotidyl transferase-mediated dUTP-fluorescein nick end labeling)-positive cells (c), lower Ki67 index (d), and lower microvessel density (CD31-positive staining) (e) than tumor-bearing mice treated with negative control (NC) anti-miR plus DXT. Quantification of apoptosis (f), proliferation (g), and angiogenesis (h) and in vivo. Data are presented as means ± s.d. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; n = 10 mice per group.